1-4 of 4
Fadi Braiteh
Close
Sort by
Journal Articles

Safety and Efficacy of Crizotinib in ALK-Positive Lymphomas: A Phase 1b Open-Label Study

Carlo Gambacorti-Passerini, MD, Sergey Orlov, Li Zhang, Fadi Braiteh, Huiqiang Huang, Taito Esaki, Keizo Horibe, Jin-Seok Ahn, Joseph T. Beck, William Jeffrey Edenfield, Yuankai Shi, Matthew Taylor, Kenji Tamura, Brian A. Van Tine, Shang-Ju Wu, MD, PhD, Jolanda Paolini, Sherry Li, Tae Min Kim
Journal: Blood
Blood (2017) 130 (Supplement 1): 4128.
https://doi.org/10.1182/blood.V130.Suppl_1.4128.4128
Published: 2017
Journal Articles

The Signature Program, a Distinctive Tissue Agnostic Trial Model for Molecularly Pre-Selected Hematological and Solid Tumor Patients

Frank Giles, MD MB, FRCPI, FRCPath, Sarina A. Piha-Paul, MD, Alexander I. Spira, PhD MD FACP, Fadi Braiteh, MD CPI, Julio Antonio Peguero, MD, Daniel L. Spitz, MD FACP, James A. Knost, MD, Lee Schwartzberg, MD FACP, Steven Stein, MD, August J. Salvado, MD, Claudia Lebedinsky, MD, Barinder Kang, PhD, Eric Slosberg, PhD
Journal: Blood
Blood (2014) 124 (21): 4818.
https://doi.org/10.1182/blood.V124.21.4818.4818
Published: 2014
Journal Articles

Safety and Clinical Activity Of Crizotinib In Patients With ALK -Rearranged Hematologic Malignancies

Carlo Gambacorti-Passerini, MD, Keizo Horibe, MD, PhD, Fadi Braiteh, MD, CPI, Hui-qiang Huang, MD, PhD, Yuankai Shi, MD, PhD, Matthew H Taylor, MD, Nicoletta Brega, Jolanda Paolini, Paulina Selaru, Tae Min Kim, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 4342.
https://doi.org/10.1182/blood.V122.21.4342.4342
Published: 2013
Journal Articles

Successful treatment of Erdheim-Chester disease, a non–Langerhans-cell histiocytosis, with interferon-α

Clinical Trials & Observations Brief Report
Fadi Braiteh, Cynthia Boxrud, Bita Esmaeli, Razelle Kurzrock
Journal: Blood
Blood (2005) 106 (9): 2992–2994.
https://doi.org/10.1182/blood-2005-06-2238
Published: 2005